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Implications for Nursing Care  
Malignant Hyperthermia 
Eric D. Weberding BSN, RN 
Definition 
 
Malignant hyperthermia (MH) is an autosomal-dominant disorder that is 
inherited. The disturbance of calcium homeostasis associated with MH affects 
skeletal muscle (Schneiderbanger, Johannsen, Roewer, & Schuster, 2014). This 
hypermetabolic muscular disorder is triggered by exposure to depolarizing 
muscle relaxants such as succinylcholine or inhaled halogenated volatile 
anesthetics such as sevoflurane, halothane, desflurane, enflurane, and isoflurane 
(Stratman, Flynn, & Hatton, 2009). In susceptible individuals, this potentially 
lethal syndrome may cause hyperthermia, hypercapnia, muscular rigidity, 







MH occurs more often in children and young adults than in the adult population. 
MH occurs more often in adult males than adult females. Distribution across 
ethnicities occurs in equal proportions (Stratman et al., 2009). While a link 
between MH and numerous myopathies is suspected, a predisposition has only 
been identified in Evans myopathy, central-core disease, and King-Denborough 
syndrome (Stratman et al., 2009).  
 
Although MH is a rare inherited disorder, this potentially life-threatening 
inherited disorder may occur approximately once in every 3,000 procedures 
involving general anesthesia (Beggs, McCann, & Powers, 2012). While obtaining 
thorough patient and family histories related to anesthesia events will reduce 
occurrences of  MH, many individuals are unaware of their own predisposition to 
this disorder and relevant family histories. More efficient treatment  of MH and 
improved understanding of the pathophysiology related to this disorder have 
resulted in an 11.7% decline in the mortality rate from MH from 2000 to 2005 
(Johns, Stoudt, Scholtis, & Gavel, 2012).  
 
However, to further improve outcomes for patients with malignant 
hyperthermia, it is imperative for multidisciplinary medical team members to 
promptly recognize early symptoms of MH, accurately diagnose this disorder, 
and respond swiftly with the appropriate treatment (Dirksen, Van Wicklin, 
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Relevance 
Signs & Symptoms 
Table 1 Clinical signs of malignant hyperthermia 
(Schneiderbanger et al., 2014, p.358) 
Individuals with MH have a mutation of the ryanodine receptor 
subtype 1 (RYR1) gene on chromosome 19q 13.1-13.2 (Li, 
Brady, Rosenberg, & Sun, 2011; Thomas & Crowhurst, 2013). 
When the dysfunctional receptor is exposed to triggering 
agents, such as halogenated volatile anesthetics and 
succinylcholine, a depolarizing neuromuscular blocking agent, 
the prolonged opening of this dysfunctional receptor occurs 
and results in the uncontrolled release of calcium within the 
skeletal muscle sarcoplasmic reticulum causing a 
hypermetabolic state in the susceptible individual (Kim, 2012).  
 
 
As a result of this uncontrolled release of calcium and 
continuous muscle activation, muscle rigidity occurs. As these 
events continue, cellular adenosine triphosphate is depleted 
resulting in protracted muscular rigidity and eventually 
rhabdomyolysis. Rhabdomyolysis occurs when cell contents 
such as creatine phosphokinase, potassium, and myoglobin are 
released into circulation due to the deterioration of the cell 
membrane. Also, in a MH event, oxygen consumption is 
increased due to the continuous activation of aerobic and 
anaerobic metabolism.  This increase in oxygen consumption 
results in acidosis, hypoxia, increased body temperature, and 
excessive production of CO2 (Schneiderbanger et al., 2014). 
Figure 1 illustrates the pathophysiological changes that occur 




Figure 1 Pathophysiologic changes during a  
MH event (Schneiderbanger  
et al., 2014 p. 357)     
Significance of  
Pathophysiology 
The following physiologic manifestations are linked  to MH: 
 
  1. Muscular rigidity most often involving the masseter: 
results from the uncontrolled and ongoing release of 
calcium from the sarcoplasmic reticulum (Schuster, 
Johannsen, Schneiderbanger, & Roewer, 2013). 
  2. Hyperthermia: results from the increased use of 
adenosine triphosphate combined with the constricting 
peripheral vasculature. The body’s ability to dissipate heat 
is markedly impaired (Schneiderbanger et al., 2014). 
 
  3. Increased ETCO2: results from an increase in myoplasmic 
calmodulin-dependent protein kinase (Ca2+). An 
unexplained increase in ETCO2 is a common and early sign 
of MH in mechanically ventilated and intubated patients 
(Kim, 2012). 
  4. Acidosis: respiratory acidosis results from increased CO2 
levels. Metabolic acidosis results from increased lactate 
levels (Dirksen et al., 2013). 
 
  5. Myoglobinuria:  results from damage to the cell 
membrane allowing intracellular contents, such as 
magnesium, potassium, creatine, and myoglobin to seep 
into the bloodstream (Dirksen et al., 2013). 
  6. Renal Failure: due to cell membrane damage, released 
myoglobin obstructs renal tubules causing acute renal 
failure (Kim, 2012). 
 
  7. Tachycardia/tachypnea: Excessive amounts of CO2 
(hypercarbia) and excessive K (hyperkalemia) in the blood 
stimulate the sympathetic nervous system resulting in 
rapid heart rate and/or rapid breathing  
(Dirksen et al., 2013). 
  8. Cardiac arrhythmias/failure: Potentially fatal 
dysrhythmias occur due to hyperkalemia and the kidneys 
inability to excrete excess K (Dirksen et al., 2013). 
 
Implications for  
Nursing Care 
 MH treatment objectives: stop the abnormal 
metabolic reaction with dantrolene and restore 
normal hemodynamic conditions, temperatures, 
and metabolic functions. (Seifert, Wahr, Pace, 
Cochrane, Bagnola, 2014) 
 
 Recommended management approach: Utilize a 
multidisciplinary medical team trained to promptly 
and accurately diagnose MH, work cooperatively, 
understand multiple roles and responsibilities, and 
efficiently utilize readily available equipment and 
medications; medical teams should periodically 
review MH protocol and participate in mock drills 
to practice tasks and roles (Dirksen, 2013) 
 
 See Figure 2 for  recommended roles and treatment  
 
Conclusions 
Figure 2 Personnel roles and treatment interventions in a MH  event  
(Seifert et al.,  2014, p. 197) 
The ultimate goal is to prevent the occurrence of MH. As discussed by Beggs, 
McCann, and Powers (2012), prior to the administration of anesthesia, obtaining 
thorough patient and family histories related to adverse anesthesia reactions may 
alert the anesthesia provider to the patient’s possible predisposition to MH and 
dictate the selection of non-triggering MH anesthesia agents. However, when 
prevention is not realized, continued vigilance and crisis preparedness on the part of 
multidisciplinary medical team members will further reduce the MH mortality rate 
and improve patient outcomes (Schneiderbanger et al., 2014).  
Early                            Late  
Masseter spasm                            Hyperthermia 
Generalized muscular rigidity           Rhabdomyolysis 
Tachycardia (>80%)                            Acute renal failure 
Hypercapnia                            Cardiac arrhythmia 
Hypoxia                            Hypotension 
Combined metabolic-                          Circulatory failure 
respiratory acidosis 
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